Joseph W. Polli
ViiV Healthcare (Spain)(ES)
Publications by Year
Research Areas
Drug Transport and Resistance Mechanisms, Pharmacological Effects and Toxicity Studies, HIV/AIDS drug development and treatment, Pharmacogenetics and Drug Metabolism, HIV Research and Treatment
Most-Cited Works
- → Membrane transporters in drug development(2010)3,297 cited
- → Rational Use of in Vitro P-glycoprotein Assays in Drug Discovery(2001)659 cited
- → Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs(2002)623 cited
- → IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES(2006)260 cited
- → An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)(2008)252 cited
- → The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions(2008)249 cited
- → In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor(2012)244 cited
- → Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver(2013)230 cited
- → Vitamin E-TPGS Increases Absorption Flux of an HIV Protease Inhibitor by Enhancing Its Solubility and Permeability1(1999)221 cited
- → Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor(1999)218 cited